| Knowledge4COVID-19

Property	Value
is ?:annotates of	<https://research.tib.eu/covid-19/entity/34648930_HAS_TOPIC_C0019907> <https://research.tib.eu/covid-19/entity/34648930_HAS_TOPIC_C0079161> <https://research.tib.eu/covid-19/entity/34648930_HAS_TOPIC_C0079990> <https://research.tib.eu/covid-19/entity/34648930_HAS_TOPIC_C0086418> <https://research.tib.eu/covid-19/entity/34648930_HAS_TOPIC_C0524612> <https://research.tib.eu/covid-19/entity/34648930_HAS_TOPIC_C0524613> <https://research.tib.eu/covid-19/entity/34648930_HAS_TOPIC_C1615608> <https://research.tib.eu/covid-19/entity/34648930_HAS_TOPIC_C5203670> <https://research.tib.eu/covid-19/entity/34648930_HAS_TOPIC_C5203676> <https://research.tib.eu/covid-19/entity/34648930_HAS_TOPIC_C5392141> <https://research.tib.eu/covid-19/entity/34648930_HAS_TOPIC_C5392189> <https://research.tib.eu/covid-19/entity/34648930_HAS_TOPIC_C5392190> <https://research.tib.eu/covid-19/entity/34648930_HAS_TOPIC_C5392970>
?:authorAffiliation	[\'Global Vaccine Epidemiology and Modelling Department (VEM)Sanofi Pasteur, Singapore. Sanofi-Aventis (Singapore) Pte. Ltd., 38, Beach Road, #18-11, South Beach Tower, Singapore; University Claude Bernard Lyon 1, Lyon, France. Electronic address: clotilde.elguerchesblain@sanofi.com.\', \'Corporate Value Associates, Paris, France. Electronic address: lina.chakir@corporate-value.com.\', \'Global Vaccine Epidemiology and Modelling Department (VEM)Sanofi Pasteur, Singapore. Sanofi-Aventis (Singapore) Pte. Ltd., 38, Beach Road, #18-11, South Beach Tower, Singapore. Electronic address: gopi.nageshwaran@sanofi.com.\', \'Global Vaccine Epidemiology and Modelling Department (VEM)Sanofi Pasteur, Singapore. Sanofi-Aventis (Singapore) Pte. Ltd., 38, Beach Road, #18-11, South Beach Tower, Singapore; Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, UK. Electronic address: rebecca.harris@sanofi.com.\', \'Sorbonne Université, INSERM, UMRS1158, Neurophysiologie Respiratoire Expérimentale et Clinique, F-75005, Paris, France. Electronic address: caroline.sevoz-couche@upmc.fr.\', \'Corporate Value Associates, Paris, France. Electronic address: olivier.vitoux@corporate-value.com.\', \'Service D\'Hygiène, Épidémiologie et Prévention, Hôpital Édouard Herriot, Hospices Civils de Lyon, Lyon, France; Epidemiology and International Health Team, Emergent Pathogens Laboratory, Fondation Mérieux, International Center for Research in Infectiology, National Institute of Health and Medical Research, U1111, National Center of Scientific Research, Mixed Scientific Unit 5308, École Nationale Supérieure de Lyon, Université Claude Bernard Lyon 1, Lyon, I-REIVAC, France. Electronic address: philippe.vanhems@chu-lyon.fr.\']
?:citedBy	-1
?:creator	<https://research.tib.eu/covid-19/entity/Chakir_Lina> <https://research.tib.eu/covid-19/entity/El_Guerche-S%C3%A9blain_Clotilde> <https://research.tib.eu/covid-19/entity/Harris_Rebecca_C> <https://research.tib.eu/covid-19/entity/Nageshwaran_Gopinath> <https://research.tib.eu/covid-19/entity/Sevoz-Couche_Caroline> <https://research.tib.eu/covid-19/entity/Vanhems_Philippe> <https://research.tib.eu/covid-19/entity/Vitoux_Olivier>
?:doi	S1477-8939(21)00212-X10.1016/j.tmaid.2021.102171
?:doi	<https://research.tib.eu/covid-19/entity/S1477-8939%2821%2900212-X10.1016/j.tmaid.2021.102171>
?:hasPublicationType	<https://research.tib.eu/covid-19/entity/Journal_Article> <https://research.tib.eu/covid-19/entity/Review>
?:journal	Travel medicine and infectious disease
is ?:pmid of	<https://research.tib.eu/covid-19/entity/34648930>
?:pmid	<https://research.tib.eu/covid-19/entity/34648930>
?:pmid	34648930
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/Covid-19>
?:rankingScore_SJR	1.098
?:rankingScore_hIndex	34
?:title	Experience from five Asia-Pacific countries during the first wave of the COVID-19 pandemic: Mitigation strategies and epidemiology outcomes.
?:type	<https://research.tib.eu/covid-19/vocab/Publication> <https://research.tib.eu/covid-19/vocab/Publication_Author>

Property

Value

is ?:annotates of

?:authorAffiliation

[\'Global Vaccine Epidemiology and Modelling Department (VEM)Sanofi Pasteur, Singapore. Sanofi-Aventis (Singapore) Pte. Ltd., 38, Beach Road, #18-11, South Beach Tower, Singapore; University Claude Bernard Lyon 1, Lyon, France. Electronic address: clotilde.elguerchesblain@sanofi.com.\', \'Corporate Value Associates, Paris, France. Electronic address: lina.chakir@corporate-value.com.\', \'Global Vaccine Epidemiology and Modelling Department (VEM)Sanofi Pasteur, Singapore. Sanofi-Aventis (Singapore) Pte. Ltd., 38, Beach Road, #18-11, South Beach Tower, Singapore. Electronic address: gopi.nageshwaran@sanofi.com.\', \'Global Vaccine Epidemiology and Modelling Department (VEM)Sanofi Pasteur, Singapore. Sanofi-Aventis (Singapore) Pte. Ltd., 38, Beach Road, #18-11, South Beach Tower, Singapore; Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, UK. Electronic address: rebecca.harris@sanofi.com.\', \'Sorbonne Université, INSERM, UMRS1158, Neurophysiologie Respiratoire Expérimentale et Clinique, F-75005, Paris, France. Electronic address: caroline.sevoz-couche@upmc.fr.\', \'Corporate Value Associates, Paris, France. Electronic address: olivier.vitoux@corporate-value.com.\', \'Service D\'Hygiène, Épidémiologie et Prévention, Hôpital Édouard Herriot, Hospices Civils de Lyon, Lyon, France; Epidemiology and International Health Team, Emergent Pathogens Laboratory, Fondation Mérieux, International Center for Research in Infectiology, National Institute of Health and Medical Research, U1111, National Center of Scientific Research, Mixed Scientific Unit 5308, École Nationale Supérieure de Lyon, Université Claude Bernard Lyon 1, Lyon, I-REIVAC, France. Electronic address: philippe.vanhems@chu-lyon.fr.\']

?:citedBy